医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Terumo BCT Opens Manufacturing Facility in Vietnam

2014年07月18日 AM02:50
このエントリーをはてなブックマークに追加


 

LAKEWOOD, Colo.

Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, today announced the opening of its new 91,440-square-meter facility near Ho Chi Minh City, Vietnam. The $100 million manufacturing facility supports the expansion of Terumo BCT’s business globally. When manufacturing operations begin in early 2015, the new manufacturing facility will provide increased production capacity.

Terumo BCT's new manufacturing facility in Vietnam. (Photo: Business Wire)

Terumo BCT’s new manufacturing facility in Vietnam. (Photo: Business Wire)

Key Facts:

  • Terumo BCT is a global medical device manufacturer headquartered in Lakewood, Colorado
  • Regional headquarters are in: Brussels, Buenos Aires, Hong Kong and Tokyo
  • With a $100M investment, Terumo BCT has built a 91,440-square-meter facility located near Ho Chi Minh City on an area of 10 hectares
  • Once fully staffed, the building is expected to accommodate more than 900 new associates
  • With the opening of the Vietnam facility Terumo BCT products will be manufactured in seven countries: Belgium, China, India, Japan, Northern Ireland, the United States and Vietnam
  • Whole blood bags and disposables for automated collections will be manufactured in Vietnam
  • Terumo BCT currently has more than 4,800 associates, and serves three primary customer segments in more than 120 countries and territories: Blood Centers, Therapeutic Apheresis and Cell Collections, and Cell Processing
  • The Vietnam facility is part of Terumo BCT’s broader strategy that includes investments in its existing U.S. manufacturing operations at its global headquarters in Colorado, and in its manufacturing facilities in Northern Ireland and India

Key Quotes:

Craig Rinehardt, Executive Vice President, Global Operations, Terumo BCT

“This completion of this manufacturing facility represents a continued commitment to our customers on every continent, by providing global capacity and advancing manufacturing techniques that will be used in Vietnam to increase product speed to market and enhance our ability to meet customers’ needs.”

“In less than a year we have broken ground, built and completed construction. With the help of so many, we have brought this investment to life and are thrilled to be opening our doors to the manufacturing facility in Vietnam, a welcome addition to our U.S. manufacturing headquarters, and to our global operations.”

Yutaro Shintaku, President and Representative Director, Terumo Corporation

“Terumo BCT’s new Vietnam facility is the most recent example of how Terumo Corporation is investing in its capabilities globally and the opening of this facility is an exciting new step for us. We are optimistic about the opportunities this new facility provides for us to participate in the region’s growth and live our mission of contributing to society through healthcare.”

Key Resources:

About Terumo BCT:

Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140717006181/en/

CONTACT

Terumo BCT
Laura Fusco, +1-303-205-2546
Global
Corporate Communications
press@terumobct.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing
  • 三叶草生物制药完成6,280万元人民币A轮融资
  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表